Advertisement

Topics

J&J biospecific antibody deal could net Zymeworks up to $2.5bn

06:45 EST 15 Nov 2017 | BioPharma-Reporter

Janssen Biotech has selected Zymeworksâ Azymetric and Effect platforms to make bispecific antibody therapeutics.

Original Article: J&J biospecific antibody deal could net Zymeworks up to $2.5bn

NEXT ARTICLE

More From BioPortfolio on "J&J biospecific antibody deal could net Zymeworks up to $2.5bn"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...